Ann M. Hanly - Feb 22, 2024 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Signature
/s/ Sung Lee, Attorney-in-Fact
Stock symbol
VIR
Transactions as of
Feb 22, 2024
Transactions value $
-$123,521
Form type
4
Date filed
2/26/2024, 07:34 PM
Previous filing
Mar 31, 2023
Next filing
Apr 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Award $0 +32.5K +28.37% $0.00 147K Feb 22, 2024 Direct F1
transaction VIR Common Stock Sale -$124K -12.3K -8.36% $10.05 135K Feb 22, 2024 Direct F2
holding VIR Common Stock 11.5 Feb 22, 2024 See footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Award $0 +65K $0.00 65K Feb 22, 2024 Common Stock 65K $10.11 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
F2 Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
F3 The shares are beneficially owned by the reporting person's spouse, for the benefit of a minor child.
F4 25% of the shares subject to the stock option vest and become exercisable on February 22, 2025, and the remainder vest in 36 equal monthly installments thereafter.